ESALY - Eisai Co., Ltd.
| Previous Close | 51.00 |
| Open | 51.14 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 50.24 - 50.73 |
| 52 Week Range | 49.89 - 101.80 |
| Volume | 11,036 |
| Avg. Volume | 6,679 |
| Market Cap | 14.476B |
| Beta (3Y Monthly) | 0.61 |
| PE Ratio (TTM) | 24.23 |
| EPS (TTM) | 2.08 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.48 (2.88%) |
| Ex-Dividend Date | 2019-03-27 |
| 1y Target Est | 80.95 |
- Benzinga
Eisai's Cancer Drug Combo Gets Breakthrough Therapy Designation For Liver Cancer
Japanese drug maker Eisai Co., Ltd (OTC: ESALY ) has some positive news concerning one of its pipeline candidates. What Happened Eisai said the FDA has granted Breakthrough Therapy Designation for Lenvima, ...
- Benzinga
The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 22) Acasti Pharma Inc (NASDAQ: ACST ) Apellis Pharmaceuticals ...
- TheStreet.com
Watch These 4 Japanese Drugmakers With Big Coming Events
Investors should keep tabs on these "focus events" from this quartet of U.S.-listed Japanese drugmakers that can make or break their treatments.
- Zacks
Xencor (XNCR) Jumps: Stock Rises 7.4%
Xencor (XNCR) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
- Zacks
The Zacks Analyst Blog Highlights: Eisai, Martin Marietta and Columbia Sportswear
The Zacks Analyst Blog Highlights: Eisai, Martin Marietta and Columbia Sportswear
- Zacks
Ocular (OCUL) Gets FDA Nod for Label Expansion of Dextenza
Ocular (OCUL) clinches the FDA approval for the label expansion of Dextenza to treat ocular inflammation following ophthalmic surgery.
- Investor's Business Daily
Why Alzheimer's Treatment Hopes Endure Despite High-Profile Drug Failures
Alzheimer's treatment continues to confound biotech companies in the wake of Biogen and Eisai's decision to terminate two late-stage tests. But scientists say there's hope in new theories.
- Zacks
Ocular's Glaucoma Drug Study Fails to Meet Primary Endpoint
Ocular's (OCUL) phase III study on OTX-TP for the reduction of intraocular pressure (IOP) in patients with primary open-angle glaucoma fails to achieve primary endpoint.
- Zacks
Catalent Acquires Gene Therapy Leader Paragon Bioservices
Catalent (CTLT) acquires gene therapy leader Paragon Bioservices for $1.2 billion.
Market RealistKey Drugs in Merck’s Oncology Portfolio
Comparing MRK’s and ABBV’s Outlook: Which Is the Better Pick?(Continued from Prior Part)Lenvima growth trendsIn the first quarter, Merck’s (MRK) and Eisai’s Lenvima reported solid uptake across multiple markets, driven mainly by demand in
- Zacks
CannTrust Holdings (CTST) in Focus: Stock Moves 6.1% Higher
CannTrust Holdings (CTST) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
- Zacks
Catalyst (CPRX) Q1 Loss Narrows, Firdapse Off to a Good Start
Catalyst (CPRX) posts narrower-than-expected loss and beats on revenues in the first quarter of 2019.
- Zacks
Zoetis (ZTS) Earnings Beat Estimates in Q1, Revenues Miss
Zoetis???s (ZTS) earnings beat estimates but sales miss the same in the first quarter of 2019.
- Benzinga
The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 30) VolitionRX Ltd (NYSE: VNRX ) ZEALAND PHARMA/S ADR ...
- Zacks
Achaogen (AKAO) Files for Bankruptcy, Shares Plunge 65%
Achaogen (AKAO) files for bankruptcy in a district court. Shares slump 65% on the announcement.
- Zacks
Zogenix Gets Refusal to File Letter From FDA for Seizure Drug
Zogenix (ZGNX) receives a Refusal to File letter from the FDA regarding its NDA for Fintepla for the treatment of seizures associated with Dravet syndrome.
- Zacks
United Therapeutics Discontinues PAH Drug After Study Fails
United Therapeutics (UTHR) discontinues the development of esuberaprost, as the phase III study fails to meet primary endpoint.
- Benzinga
The Daily Biotech Pulse: Safety Board Clears Eisai's Alzheimer's Study, Positive Trial Results For Galapagos-Gilead
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 28) Baxter International Inc (NYSE: BAX ) Constellation ...
- Reuters
Nikkei posts biggest daily drop in 3 months on renewed fears of global slowdown
On Friday, the spread between yields of U.S. three-month Treasury bills exceeded those of 10-year notes for the first time since 2007. The inversion of the Treasury yield curve suggested the world's largest economy could slide into recession and reignited fears of a deepening slowdown in the global economy. "Insurers react negatively as it becomes harder for them to manage assets," said Eiji Kinouchi, chief technical analyst at Daiwa Securities.
- Reuters
Nikkei hits five-week low on renewed fears of global slowdown
Japan's Nikkei sold off sharply on Monday as investors moved into bonds and other assets perceived as safe amid renewed fears of a global economic slowdown. The benchmark index was on track for its steepest daily fall in percentage terms since losing 5 percent in late December. On Friday, the spread between yields of U.S. three-month Treasury bills exceeded those of 10-year notes for the first time since 2007.
- Investor's Business Daily
Biogen Skids On Alzheimer's Flop — And Unveils Yet Another Study
Biogen and Japanese pharma Eisai announced a new study in Alzheimer's disease treatment Friday following a high-profile failure on Thursday that sent Biogen stock into a tailspin.
- Benzinga
Analysts Digest Biogen's Alzheimer's Disappointment: 'There Isn't Much To Be Excited About'
Mizuho Securities analyst Salim Syed downgraded Biogen from Buy to Neutral and slashed the price target from $416 to $235. UBS analyst Carter Gould downgraded Biogen from Buy to Neutral and reduced the price target from $395 to $242. Morgan Stanley analyst Matthew Harrison downgraded shares from Overweight to Underweight and slashed the price target from $401 to $210.
- Benzinga
Eisai Launches Confirmatory Late-Stage Trial Of Second Alzheimer's Asset After Setback
Eisai, which is partnering with Biogen Inc (NASDAQ: BIIB) on Alzheimer's research, announced the initiation of a global Phase 3 clinical study Thursday, dubbed Clarity AD/Study 301, of BAN2401, which is being evaluated in patients with early Alzheimer's disease. BAN2401 is a monoclonal antibody that acts against beta-amyloid protein that forms clumps called plaques in the brain, impairing connections between brain cells and triggering inflammation, leading to cell death, both of which are responsible for the onset of Alzheimer's.
